RSNA 2014 

Abstract Archives of the RSNA, 2014


NME106

Spectrum of Findings on 123I Ioflupane (DatScan) Imaging : Normal, Abnormal, Artifacts and Interpretative Pitfalls

Education Exhibits

Presented on December 3, 2014
Presented as part of NMS-WEA: Nuclear Medicine Wednesday Poster Discussions

Participants

Valeria Moncayo MD, Presenter: Nothing to Disclose
Bruce Jonathan Barron MD, Abstract Co-Author: Stockholder, Immunomedics Inc
Raghuveer K. Halkar MD, Abstract Co-Author: Research Grant, General Electric Company Research Grant, Gilead Sciences, Inc Royalties, General Electric Company
Hulegar Ashok Abhishekh, Abstract Co-Author: Nothing to Disclose
James Roland Galt PhD, Abstract Co-Author: Nothing to Disclose
David M. Schuster MD, Abstract Co-Author: Research funded, Nihon Medi-Physics Co, Ltd Expert Advisory Committee, AIM Specialty Health
Ayse Tuba Karagulle Kendi MD, Abstract Co-Author: Nothing to Disclose

TEACHING POINTS

• Since it’s approval in 2012, 123I Ioflupane is widely used in the United States to aid the evaluation of patients with suspected Parkinson’s disease.   • Nuclear medicine practitioners interpreting these studies most commonly use visual qualitative analysis to determine if a study is normal of abnormal.   • Difficult to interpret cases are not uncommon, in certain cases, quantitative evaluation with the putamen/caudate/background ratios are useful. • A collection of cases from our Database will be presented with a literature supported approach. After viewing this exhibit the learner will become familiar with the different aspects fo DatScan imaging and will be exposed to a number of cases to enrich his/her experience for interpretation in clinical practice.  

TABLE OF CONTENTS/OUTLINE

• Principles of DatScan imaging • Imaging protocol of DatScan • Importance of DatScan and its role in the diagnostic process of Parkinson’s Disease and other Parkinsonian Syndromes. • Interpretative approach, other examples: - Normal - Abnormal - Borderline cases - Common artifacts -Non diagnostic cases - Effect of medication in the interpretation of DatScan  examples - Quantitative evaluation tools and their limitations.  examples  

PDF UPLOAD

http://abstract.rsna.org/uploads/2014/14007682/14007682_53gv.pdf

Cite This Abstract

Moncayo, V, Barron, B, Halkar, R, Abhishekh, H, Galt, J, Schuster, D, Karagulle Kendi, A, Spectrum of Findings on 123I Ioflupane (DatScan) Imaging : Normal, Abnormal, Artifacts and Interpretative Pitfalls.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007682.html